See today's BioWorld Science
To read the full story, subscribe or sign in.
Respiratory

Kymera’s oral STAT degrader KT-621 gains IND clearance from FDA

Oct. 10, 2024
Kymera Therapeutics Inc. has received IND clearance from the FDA for KT-621, an investigational first-in-class, once-daily, oral STAT6 degrader.
BioWorld Science Regulatory Dermatologic Immune Respiratory Degradation inducer FDA IND